Biocon Limited — PPTs, 09-05-2025: Investor Presentation

1. Financial Highlights:

Biocon posted consolidated revenue of ₹4,454 Cr in Q4 FY25, up 15% YoY and 1% QoQ, driven by broad-based segment growth. FY25 revenue grew 8% YoY to ₹16,470 Cr. Core EBITDA rose 16% YoY in Q4 to ₹1,363 Cr, with margin expansion to 31%; FY25 Core EBITDA stood at ₹4,264 Cr with 28% margin. Net profit before exceptional items surged 139% YoY in Q4 to ₹333 Cr, reaching ₹981 Cr for FY25. Generics revenue jumped 46% YoY in Q4 to ₹1,048 Cr, fueled by US and UK launches; biosimilars increased 5% QoQ to ₹2,463 Cr. Syngene’s research services crossed ₹1,000 Cr quarterly revenue for the first time. R&D spend remained healthy at 7-9.5% of segment revenues.

2. Strategic Initiatives & Growth Drivers:

Biocon launched its first GLP-1 peptide (Liraglutide) globally with approvals across UK and EU, alongside US launches of Lenalidomide and Dasatinib, bolstering its generics pipeline. The peptide segment, especially GLP-1s, is a key growth focus. Syngene enhanced its biologics CDMO capacity by acquiring a US manufacturing facility, addressing rising demand. Innovation, digital integration, and operational efficiency remain priorities to sustain growth momentum.

3. Business Developments:

Notable product rollouts include Yesintek (Stelara® biosimilar), Jobevne (Bevacizumab biosimilar), and regulatory advances with USFDA nod for Jobevne and EMA’s positive opinion on bDenosumab. Market entry for Yesafili (bAflibercept) in the US is targeted by H2 FY26. A partnership with Civica Inc. supports affordable insulin accessibility in the US. Tacrolimus supplies to China have commenced via partners anticipating commercialization soon.

4. Market Position & Competitive Advantage:

Biocon holds strong leadership in biosimilars, with multiple products exceeding USD 200 million revenue marks, reflecting solid payor and prescriber trust. A well-diversified portfolio across generics, biosimilars, and CRDMO services provides scale benefits. Recent regulatory clearances in the US and EU expand its global footprint, while Syngene’s US biologics manufacturing boost enhances competitiveness in the growing biologics outsourcing space.

5. Investor Implications:

Biocon exhibits positive growth potential driven by successful new launches and strategic expansions in high-margin biosimilars and peptides. Margin improvement through operational leverage supports earnings growth. Execution on pipeline commercialization, integration of new facilities, and monitoring pricing dynamics in generics are key factors for investors to watch.